This study is looking at using different experimental treatment methods for children diagnosed with Acute Myeloid Leukemia (AML) and Down Syndrome (DS) based on how well they respond to their first treatment.
Seeking children and young adults whose CD22+ B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) for a study of an investigational drug. While the investigational drug has been approved for use adults with leukemia, it has not yet been approved for use in children.
Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).
Seeking children and young adults 31 years old or younger who have been newly diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B ALL or localized B-cell Lymphoblastic Lymphoma (B-LLy) for a study of chemotherapy.
Seeking people aged 2-21 years who have been diagnosed with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive Acute Lymphoblastic Leukemia (ALL) for a study of whether using a less toxic chemotherapy in combination with a drug called imatinib can keep the cancer from returning after treatment.
Seeking men and women with advanced relapsed, refractory, or resistant hematological (blood) cancer with an IDH mutation that has not responded or stopped responding to prior treatment for participation in a study of an investigational drug.
Seeking male and female participants under the age of 25, who were diagnosed with Chronic Myeloid Leukemia before the age of 18, to determine if they can stop taking their TKI medication and remain in remission as well as if restarting TKI will re-achieve remission.
Seeking men and women who have Myelofibrosis bone marrow cancer and are not going to have a stem cell transplant for a study of an investigational drug reduce spleen volume and improve symptoms of Myelofibrosis.
Seeking men and women newly diagnosed with untreated acute myeloid leukemia (AML) who are unable to have chemotherapy for a study of an investigational drug in combination with the standard treatment.
Seeking men and women whose multiple myeloma has returned or has not responded to their most recent treatment for a study adding an investigational drug to the usual treatment.
Seeking men and women aged 18-65 years whose large B-Cell lymphoma has not responded or come back after treatment for a study of an investigational drug combination.
Seeking men and women with with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia for a study of an investigational drug to reduce spleen volume.
Seeking men and women over 18 years of age who have relapsed or refratory B-cell lymphoma after first line chemoimmunotherapy for participation in a study looking at an investigational drug in combination with other drugs
Seeking men and women who have Multiple Myeloma (MM) and will undergo Autologous Stem Cell Transplant (ASCT) as a form of treatment for a study of an investigational drug to help collect blood stem cells.